[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 3 sources · 24 days · First seen · Last updated

Global pharmaceutical and biotech industry trends

Overview

The global biotechnology and pharmaceutical sectors have experienced significant activity driven by strategic acquisitions and regulatory milestones. Between January and May 2026, the biotech sector saw 201 mergers and acquisitions totaling approximately $106 billion. This surge is largely attributed to a looming “patent cliff,” where companies are paying premiums of 38% to 140% to secure strategic assets in oncology, obesity, and gene therapies.

Following this period of intense M&A activity, the industry has seen shifts in market leadership, with Eli Lilly ascending to the number one spot in industry rankings. Regulatory developments also progressed, notably with the FDA granting accelerated approval to Bristol Myers Squibb’s Zenbexus for treating multiple myeloma. Concurrently, institutional investors have adjusted their holdings in major pharmaceutical firms, including Amgen and Bristol Myers Squibb.

Entities

Pharming Group N. V. · Ameriprise Financial, Inc. · Eli Lilly · Amgen Inc. · FDA

Timeline

  1. 27 days ago

    [BUSINESS] 3 sources
    Pharmaceutical industry sees leadership shifts and FDA approvals

    Eli Lilly has risen to number one in pharmaceutical rankings, while Bristol Myers Squibb received FDA accelerated approval for Zenbexus. Major institutional investors are also adjusting stakes in Amgen and Amer

  2. about 2 months ago

    [BUSINESS] 2 sources
    Biotech firms surge ahead with $106 bn in acquisitions as patent cliff approaches

    Biotech M&A hits $106 bn in early 2026 as firms scramble to fill gaps before a major patent cliff, with mega‑deals by Eli Lilly, Pfizer, Gilead and others.

Sources

mommygearest.com · pharmexec.com · stocknews.com